SEARCH

SEARCH BY CITATION

References

  • 1
    Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172:34227.
  • 2
    Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen–antibody complexes by rheumatoid factor B cells. J Exp Med 1991; 173:4879.
  • 3
    Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167:47108.
  • 4
    Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:257281.
  • 5
    Lequerre T, Jouen F, Brazier M et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxf) 2007; 46:44653.
  • 6
    Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:31524.
  • 7
    Dupuy AM, Badiou S, Descomps B, Cristol JP. Immunoturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination. Clin Chem Lab Med 2003; 41:9489.
  • 8
    Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793806.
  • 9
    Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position –857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxf) 2005; 44:54752.
  • 10
    De Vries N, Tak PP. The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology (Oxf) 2005; 44:7057.
  • 11
    Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha –308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006; 27:15761.
  • 12
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position −308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48:184952.
  • 13
    Seitz M, Wirthmuller U, Moller B, Villiger PM. The −308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxf) 2007; 46:936.
  • 14
    Guis S, Balandraud N, Bouvenot J et al. Influence of −308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007; 57:142630.
  • 15
    Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxf) 2006; 45:155865.
  • 16
    Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:19329.
  • 17
    Mugnier B, Roudier J. Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 2004; 71:914.
  • 18
    Weaver AL, Lautzenheiser RL, Schiff MH et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006; 22:18598.
  • 19
    Wolbink GJ, Voskuyl A, Lems WF et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:7047.
  • 20
    Bargnoux AS, Bonardet A, Chong G et al. Evaluation of an immunoassay (Abbott-IMX Analyzer) allowing routine determination of sirolimus: comparison with LC-MS method. Transplant Proc 2006; 38:23523.
  • 21
    Buch MH, Seto Y, Bingham SJ et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005; 52:428.
  • 22
    Drynda S, Ringel B, Kekow M et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol Res Pract 2004; 200:16571.
  • 23
    Jarvis JN, Centola M. Gene-expression profiling: time for clinical application? Lancet 2005; 365:199200.
  • 24
    Lequerre T, Vittecoq O, Le Loet X. Comments about the editorial by Benedicte Mugnier and Jean Roudier entitled ‘Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 2005; 72:3467; author reply 7–8.
  • 25
    Wolbink GJ, Groot E DE, Lems WF, Nurmohamed MT, Tak T, Dijmans BAC. Relationship between serum levels of infliximab, C-reactive protein and clinical response to infliximab patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62 (SI):98 (abstract).
  • 26
    Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:15218.
  • 27
    Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:16396.
  • 28
    Taylor PC, Peters AM, Paleolog E et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43:3847.
  • 29
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:52933.
  • 30
    Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N, Giron-Gonzalez JA. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-α blockade in patients with rheumatoid arthritis. J Rheumatol 2005; 32:21028.
  • 31
    Dupuy AM, Lehmann S, Cristol JP. Protein biochip systems for the clinical laboratory. Clin Chem Lab Med 2005; 43:1291302.
  • 32
    Lequerre T, Gauthier-Jauneau AC, Bansard C et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R105.
  • 33
    Magrini F, Grunert VP, Eberl H, Karl J, Wild N, Zolg W. Correlation of serum biochemical markers with response to treatment of rheumatoid arthritis with rituximab. ACR congress, 2005. Abstract 1461.
  • 34
    Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58:156675.
  • 35
    Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006; 65 (Suppl. 3):iii215.
  • 36
    Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005; 51:116576.
  • 37
    Di Serio F, Amodio G, Ruggieri E et al. Proteomic approach to the diagnosis of acute coronary syndrome: preliminary results. Clin Chim Acta 2005; 357:22635.
  • 38
    Badiou S, Cristol JP, Jaussent I et al. Fine tuning of the prediction of mortality in hemodialysis patients by use of cytokine. Clin J Am Soc Nephrol 2008; 3:42330.
  • 39
    Hrycaj P, Korczowska I, Lacki JK. Infliximab in rheumatoid arthritis: can the response be predicted? Ann Rheum Dis 2003; 62 (SI):403 (abstract).
  • 40
    Moller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006; 27:391408.
  • 41
    Brieland JK, Flory CM, Jones ML et al. Regulation of monocyte chemoattractant protein-1 gene expression and secretion in rat pulmonary alveolar macrophages by lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1 beta. Am J Respir Cell Mol Biol 1995; 12:1049.
  • 42
    DeForge LE, Kenney JS, Jones ML, Warren JS, Remick DG. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J Immunol 1992; 148:213341.
  • 43
    Koch AE, Kunkel SL, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90:7729.
  • 44
    Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS. Overlapping gene expression profiles in rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor. Inflamm Res 2005; 54:106.
  • 45
    Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem 2005; 280:1743548.
  • 46
    Zhou A, Scoggin S, Gaynor RB, Williams NS. Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene 2003; 22:205464.
  • 47
    Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 1993; 69:8391.
  • 48
    Haynes PP Youssef, DR, Triantafillou S et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997; 40:14008.
  • 49
    Satoh K, Kikuchi S, Sekimata M, Kabuyama Y, Homma MK, Homma Y. Involvement of ErbB-2 in rheumatoid synovial cell growth. Arthritis Rheum 2001; 44:2605.
  • 50
    Klooster AR, Bernier SM. Tumor necrosis factor alpha and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte. Arthritis Res Ther 2005; 7:R12738.
  • 51
    Fabre S, Dupuy AM, Dossat N et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008; 153:18895.